Get App
Last Updated : May 16, 2018 06:50 PM IST | Source:

Buy Thyrocare Technologies; target of Rs 795: Prabhudas Lilladher

Prabhudas Lilladher is bullish on Thyrocare Technologies has recommended buy rating on the stock with a target price of Rs 795 in its research report dated May 04, 2018.

Broker Research @moneycontrolcom
  • bselive
  • nselive
Todays L/H

Prabhudas Lilladher's research report on Thyrocare Technologies

Thyrocare's sales, EBITDA and Adj. PAT grew 11%, 18% and 29% YoY respectively in Q4FY18. While sick care business revenue grew 27%, the revenues from preventive care declined by 11% YoY due to increased competition from unorganized players and reduced promotional costs. Management guided for increased focus on B-2-B business and maintained similar B-2-C growth by spending 4-5% of sales in advertisements in FY19E.


We expect benefits of lower price and promotions to be realised with lag effect and may have a J-curve impact on EBITDA margins. We lower our earnings estimates by 18% in FY19E as well as expect the earnings growth to be slower in FY20 at 22%. This has led to reduction in TP to Rs795 (previously Rs967) at a target PER of 35x FY20E.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Moneycontrol Ready Reckoner
Now that payment deadlines have been relaxed due to COVID-19, the Moneycontrol Ready Reckoner will help keep your date with insurance premiums, tax-saving investments and EMIs, among others.

Facebook-BCG report suggests these measures for businesses to unlock the changing consumer behaviour in the current pandemic. Read More!

First Published on May 16, 2018 06:50 pm
Follow us on